Although breast cancer was once considered a “non-immunogenic” cancer, numerous studies demonstrate PD-L1 expression in the breast cancer micro-environment, and now several immune checkpoint inhibitors are under investigation in this patient group. To help us to interpret the results of all of these trials and to begin thinking about how this class of drugs fits into breast cancer treatment plans, we’ve invited Professor Peter Schmid, Centre Lead of the Centre of Experimental Cancer Medicines at Bart’s Cancer Institute, London, to answer our questions on the topic.

References: 
Plaines-Laine, et al. Cancers (Basel). 2019; 11(7): 1033
Cyprian, et al. Bosn J Basic Med Sci. 2019; 19(3): 227-233
Schmid, et al. N Engl J Med. 2020 Feb 27;382(9):810-821
Access more free education today! Visit the website, follow us on Twitter (@onckip) or connect on LinkedIn.
This episode is supported by an educational grant from Merck, Sharpe and Dohme corp., who has had no influence on the content or choice of faculty.